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Oncolytic viruses capable of tumor-selective replication and cytolysis have shown early promise as cancer therapeutics. We have
developed replication-competent attenuated herpes simplex virus type 1 (HSV-1) mutants, named HF10 and Hh101, which have
been evaluated for their oncolytic activities. However, the host immune system remains a significant obstacle to effective
intraperitoneal administration of these viruses in the clinical setting. In this study, we investigated the use of these HSV-1 mutants as
oncolytic agents against ovarian cancer and the use of human peritoneal mesothelial cells (MCs) as carrier cells for intraperitoneal
therapy. MCs were efficiently infected with HSV-1 mutants, and MCs loaded with HSV-1 mutants caused cell killing adequately
when cocultured with cancer cells in the presence or absence of HSV antibodies. In a mouse xenograft model of ovarian cancer, the
injection of infected carrier cells led to a significant reduction of tumor volume and prolonged survival in comparison with the
injection of virus alone. Our results indicate that replication-competent attenuated HSV-1 exerts a potent oncolytic effect on
ovarian cancer, which may be further enhanced by the utilization of a carrier cell delivery system, based on amplification of viral
load and possibly on avoidance of neutralizing antibodies.
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Introduction
In Japan, 8000 cases of ovarian cancer are newly
diagnosed and more than 4000 women die of this disease
every year.
1 Ovarian cancer has a high fatality rate
because of the lack of effective screening strategies and
the absence of symptoms during the early stage of disease.
Thus, most patients with ovarian cancer present with
advanced-stage disease in conjunction with intraperito-
neal carcinoma. Advanced epithelial ovarian cancer
(EOC) is a highly chemosensitive solid tumor with good
response rates to first-line chemotherapy. However, the
majority of patients eventually relapse, and ultimately die
of recurrent chemoresistant disease. Therefore, novel
therapeutic approaches are required. EOC remains
localized within the peritoneal cavity in a large proportion
of patients, causing local morbidity and lethal complica-
tions.
2 Owing to its localized nature, EOC lends itself to
intraperitoneal approaches to therapy, including gene
therapy.
Oncolytic virotherapy is a promising anticancer therapy
because efficient transduction and cancer cell-specific
viral replication can boost therapeutic efficacy.
3–7 There-
fore, oncolytic viral therapy is viewed as a new strategy
for the treatment of advanced cancers. Many published
reports describe the effectiveness of genetically engineered
herpes simplex virus type 1 (HSV-1). HSV-1 has many
advantages over other viruses for cancer gene therapy: (1)
it has a broad host range and high efficiency of infection;
(2) it has a large genomic capacity and can be engineered
to deliver therapeutic transgenes;
8,9 and (3) it can be
controlled by anti-herpetic drugs. Unlike retroviruses, the
HSV genome does not integrate into the host genome,
eliminating concerns of insertional mutagenesis. Clinical
trials with several of these agents have been completed,
with some efficacy. However, as the majority of those
studies have relied on direct administration into target
tissue, effective systemic viral delivery is required.
A major theoretical impediment to systemic application
of HSV is pre-existing antiviral immunity. Almost all
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www.nature.com/cgtindividuals 430 years (about 80%) have circulating
anti-HSV-1 antibodies in Japan.
10 Virus particles injected
into the peritoneal cavity are vulnerable to inactivation by
complement proteins, uptake by the reticuloendothelial
system and neutralization by circulating antibodies.
11
Of these host defenses, antibodies are likely to be the most
restrictive barrier to therapy, as they mediate a long-
lasting state of immunity to repeated infections.
12 Several
widely differing approaches aimed at protecting viral
particles within the circulation and ensuring tumor delivery
are currently the focus of intense research. For example,
one possibility is modification of the viral coat,
13,14
although such technologies are technically challenging. In
addition, cellular carriers could be used as Trojan Horse
vehicles to shield oncolytic virus (OV) from neutralization
following intraperitoneal administration, and act as in situ
virus factories once arriving at the tumor site.
15,16
In this study, we demonstrate that the molecular
engineering of cellular carriers can increase their ability
to support viral replication, promote direct cell-to-cell
viral infection of the tumor, and shield oncolytic virus
from neutralizing antibodies during delivery in vitro.
Furthermore, we show the suitability of human peritoneal
mesothelial cells (MCs) as a carrier system for delivery of
HF10 and Hh101 to maximize the efficacy of oncolytic
virus in vivo.
Materials and methods
Cell lines and viruses
Human ovarian cancer (SKOV3) cells were generously
donated by Memorial Sloan-Kettering Cancer Research
Laboratory. African green monkey kidney (Vero) cells
were obtained from the Riken Cell Bank (Tsukuba,
Ibaragi, Japan). SKOV3 cells were maintained in RPMI
1640 supplemented with 10% fetal calf serum and
penicillin–streptomycin. Vero cells were grown in Eagle’s
minimal essential medium containing 10% calf serum and
1% penicillin–streptomycin. These cells were incubated at
371C in a humidified atmosphere of 5% CO2.
hrR3, a ribonucleotide reductase (UL39)-deficient HSV-1
mutant, derived from the parental wild-type strain KOS,
was kindly provided by Sandra K Weller (University of
Connecticut Health Center, Farmington, CT). HF10 is a
non-selected clone derived from HSV-1 strain HF and
causes extensive cell membrane fusion in infected cells.
Hh101 is a recombinant virus clone isolated from Vero cells
co-infected with HF10 and hrR3 (Figure 1). The pheno-
types of these viruses have been previously described.
17–19
To visualize viruses in vitro and in vivo, the green
fluorescent protein (GFP) gene was inserted into HF10
under control of the cytomegalovirus (CMV) promoter, in
which UL43 was deleted. We named this virus HF-GFP.
Establishment and characterization of immortalized
MCs
Human peritoneal MCs were isolated from surgical
specimens of human omentum after obtaining consent
from each patient, as described previously.
20 Briefly, small
pieces of omentum were surgically resected under sterile
conditions and were trypsinized at 371C for 30min. The
suspension was then passed through a 200-mm pore nylon
mesh to remove undigested fragments, and centrifuged at
2000r.p.m. for 5min. The collected cells were cultured in
RPMI 1640 supplemented with 10% fetal calf serum. In
the subsequent experiments, cells were used during the
second or third passage after primary culture.
Lentiviral vector plasmids were constructed by recom-
bination using the Gateway system (Invitrogen, Carlsbad,
CA). Briefly, hTERT, human cyclin D1 and human
mutant Cdk4 (Cdk4R24C: an inhibitor resistant form of
Cdk4) were first recombined into entry vectors by BP
reaction (Invitrogen). Then these segments were recom-
bined with a lentiviral vector, CSII-CMV-RfA, by LR
reaction (Invitrogen) to generate CSII-CMV-hTERT,
-cyclin D1 and -hCDK4R24C. The production of recom-
binant lentiviruses with the vesicular stomatitis virus G
glycoprotein was as described previously.
21 Following the
addition of recombinant viral fluid to MCs in the presence
of 4mgml
–1 polybrene, infected cells were selected in the
presence of 250mgml
–1 of G418, 0.5mgml
–1 of puromy-
cin, 3mgml
–1 of blasticidin-S or 50mgml
–1 of hygromycin-
B. These cells are named human omentum mesothelial
cells (HOmMCs). The study to establish immortalized
MCs was approved by the local ethics committee and
institutional review board of our hospital.
Anti-HSV-1 serum
Anti-HSV-1 serum was obtained from mice or guinea pigs
by intravenous injection of HSV-1 grown in Vero cells.
The neutralizing capacity of antiserum was determined by
mixing about 100 plaque-forming units (PFU) of HSV-1
with serial dilutions of antiserum. The serum titer was
Figure 1 Models of the structures of herpes simplex virus type 1
(HSV-1) mutants. A schematic representation of the structure of the
Hh101 and HF10 genomes. The locations of deletions and insertions
in the genome of HF10 are shown. Expansions indicate the positions
of genes within the deletion and insertion regions. Arrows indicate
the position and orientation of genes within the expansions.
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Cancer Gene Therapyexpressed as the dilution causing 50% plaque reduction:
the neutralization titers of anti-HSV-1 mouse antiserum
and anti-HSV-1 guinea pig antiserum were 1000 and 1600,
respectively.
Viral replication assay
MCs or HOmMCs were plated on 35-mm dishes at a
density of 3.7 10
5 cells per dish in 2ml of the growth
medium under standard conditions overnight. Cells were
then infected with HF10 or Hh101 at multiplicities of
infection (MOI) ranging between 0.03 and 3. To measure
virus replication, cells were scraped from dishes at the
indicated times, lysed by freeze–thaw and centrifuged at
3000r.p.m. for 5min. Viral titers were determined from
the sample supernatants by plaque assay.
In vitro delivery of HSV using MCs as carriers
MCs were infected with Hh101 (MOI, 3) for 1h at 371C;
free virus was then removed and the cells were washed
with phosphate-buffered saline (PBS) three times and
resuspended in fresh medium. At 2h after infection, the
infected cells were trypsinized. The suspension was
centrifuged at 1300r.p.m. for 5min at 41C. The collected
cells were used as infected carrier cells.
SKOV3 cells were plated on 35-mm dishes at a density of
5.6 10
5 cells per dish in 2ml of the growth medium. After
24h, Hh101- (3 10
5PFU) or Hh101-infected carrier cells
(1 10
5 cells, MOI, 3) were added to the media, and we
observed any resulting cytopathogenic effects (CPEs). At
24h after infection, viral titers were determined from the
sample supernatants by plaque assay.
In vitro effects of anti-HSV-1 antiserum on HF-GFP
HOmMCs were infected with HF-GFP (MOI, 3) for 1h
at 371C; free virus was then removed and the cells were
washed with PBS three times and resuspended in fresh
medium. At 2h after infection, the infected cells were
trypsinized. The suspension was then centrifuged at
1300r.p.m. for 5min at 41C. The collected cells were
used as infected carrier cells.
SKOV3 cells were plated on 35-mm dishes. After 24h,
HF-GFP (10
5PFU per dish) or HF-GFP-infected carrier
cells (10
4 cells per dish) were added to the media with or
without anti-HSV-1 mouse antiserum. At 24h after
infection, SKOV3 cells were photographed using the
Leica (Wetglar, Germany) M205FA fluorescence stereo-
microscope with a standard GFP filter set. At 30h,
SKOV3 cells were fixed with 4% formaldehyde and stained
with 0.2% crystal violet solution. The number of plaques
was counted under microscopy. The graphs (Figure 5e)
were obtained from two independent experiments.
Animal studies
Animal studies were performed in accordance with
guidelines issued by the Animal Center at Nagoya Univer-
sity School of Medicine. Female Balb/c slc nu/nu mice
(5 to 6 weeks old) were purchased from Japan SLC
(Hamamatsu, Japan). For surgical procedures, mice were
anesthetized with an intraperitoneal injection of 7.2%
chloral hydrate in sterile PBS (0.005mlg
–1 body weight).
Subcutaneous tumor model
To determine the therapeutic efficacy of HF10, we used a
subcutaneous (s.c.) tumor model. SKOV3 cells were
cultured and passaged twice in vitro, and 5 10
6 cells
were injected s.c. into the flanks of 5-week-old nude mice.
At 8 days after tumor challenge, when s.c. tumors were
B10–15mm in diameter, mice were treated with intratu-
moral (i.t.) injection of HF10 (1 10
7PFU). Animals
in the first group were injected on days 8, 10 and 12.
Animals in the second group were injected on days 8, 10,
12, 18, 20 and 22. Control mice were treated with i.t.
injection of 1ml PBS. Tumor volume was monitored for
the indicated number of days after treatment.
Intraperitoneal tumor model
We confirmed that intraperitoneal (i.p.) injection of
SKOV3 cells into 6-week-old female Balb/c nude mice
resulted in peritoneally disseminated tumors, ascites,
cachexia and death. To assess the efficacy of Hh101, this
murine xenograft model was used. Nude mice (n¼27)
were engrafted i.p. with 2 10
6 SKOV3 cells. HOmMCs
were infected for 2h with MOI¼3 of Hh101 and
were used as carriers. After freezing and thawing at 2h
after infection, B5 10
4PFU of Hh101 were detected as
infectious viruses. To estimate the effect of Hh101 in
minimally spread ovarian cancer, HOmMCs (3 10
6 cells)
infected with Hh101 were injected i.p. on days 3, 6 and 9.
The control groups received 1ml PBS or Hh101
(5 10
4PFUml
–1) by i.p. injection on the same days. Mice
of each group were followed up to record survival times.
To evaluate the role of Hh101 in more advanced
disease, SKOV3 tumors were allowed to grow for 6 days
before they were treated. Female Balb/c nude mice
(6 weeks old )(n¼10) were engrafted i.p. with 2 10
6
SKOV3 cells, and this animal group was treated with
repeated injection on days 6, 9, 12, 15 and 18. Animals
were followed up daily to record survival times.
Localization of virus-associated GFP expression in mice
with disseminated ovarian cancer
Female Balb/c nu/nu mice (6 weeks old) were engrafted
i.p. with 2 10
6 SKOV3 cells. On day 30, mice were
randomized into two cohorts (control, HF-GFP treat-
ment group). The control group received i.p. administra-
tion of 1ml PBS. The HF-GFP treatment group was
given 10
7PFU of HF-GFP i.p. After 24h, mice were
killed and tumors were examined using the Leica
M205FA automated fluorescence stereomicroscope with
a standard GFP filter set.
To assess the effect of anti-HSV-1 antiserum by using
infected carrier cell, we injected control serum or anti-
HSV-1 guinea pig antiserum of (500ml per each mouse,
 1/100 dilution) i.p. into each mouse at 1h before
treatment. HOmMCs were preinfected with HF-GFP
(MOI, 3) for 2h and were washed in PBS. For this
experiment, a disseminated ovarian cancer model (1 10
7
SKOV3 cells, i.p.) was established in 6-week-old female
Balb/c nu/nu mice. On day 14, mice were randomized
qinto control, HF-GFP and HF-GFP-infected HOmMCs
groups. The HOmMCs group was treated with 10
7 cells of
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the intra-abdominal images were obtained by the fluores-
cence stereomicroscope. For each experiment, images were
captured under identical exposure settings. Overlays were
generated using Adobe Photoshop CS software (Adobe
Systems, San Jose, CA).
Statistical methods
Data were analyzed using the StatView statistical software
package (SAS Institution, Cary, NC). The survival data
were analyzed using the Kaplan–Meier method and the log-
rank test. Differences in tumor volumes between the treated
and control groups were analyzed by the Student’s t-test.
P-values o0.05 were considered statistically significant.
Results
Intratumoral Administration of HSV mutants suppresses
s.c. tumor growth of human ovarian cancer cells
in nude mice
We examined the ability of HF10 to control tumor cell
growth in an in vivo model. We used an s.c. tumor model,
because HF10 is fatal to immunodeficient animals when it
is administered intravenously or intraperitoneally. The
flanks of Balb/c-nu mice were s.c. injected with 5 10
6
SKOV3 cells. When tumors were palpable (day 8), i.t.
injections of PBS or HF10 (1 10
7PFU) were made on
days 8, 10 and 12 for group one, and on days 8, 10, 12, 18,
20 and 22 for group two. Injections (i.t.) with HF10
significantly reduced tumor growth compared with PBS-
injected control animals (Figure 2a). Moreover, in group
two, complete disappearance of tumors was observed in
some animals (Figure 2b). Representative pictures of
control and HF10-injected mice are shown (Figure 2c).
In vitro replication of HSV mutants in MCs,
immortalized HOmMCs and SKOV3 cells
To determine which cell line might be adequate for use as
a carrier, we next tested the ability of HF10 and Hh101 to
replicate in MCs, immortalized human omentum MCs
and in SKOV3 cells. Human MCs may pose considerable
advantages as vehicles for oncolytic virotherapy for
ovarian cancer. First, MCs can be isolated from patients
and grown in culture relatively easily. In addition, if
isolated from the same patient that will be treated,
autologous transplantation overcomes the difficulties
related to immune rejection of the transplanted cells.
Cells were infected at MOIs of 3 or 0.03. At MOI of 3,
virus titers were B10-fold higher in HOmMCs than in
MCs or SKOV3 cells at 24h after infection (Figures 3e, f).
This correlated with the observation of more extensive
and rapid CPEs in HOmMCs than SKOV3 cells (Figure
3c, d). Moreover, viral titers of MCs and SKOV3 cells
infected at MOI of 3 and HOmMCs infected at MOI of
0.03 increased equally with time. Virus replication was the
most efficient in HomMCs; thus these findings suggested
that HOmMCs would be suitable for use as carrier cells.
In vitro delivery of HSV using MCs as carrier cells
We estimated the efficacy of tumor killing caused by
virus-loaded carrier cells in vitro. To this end, the
oncolytic effects of tumor cells cocultured with virus-
loaded MCs was compared with direct infection by virus.
We administered Hh101- (3 10
5PFU) or Hh101-in-
fected carrier cells (1 10
5 cells; MOI of 3) to the media
of SKOV3 cells. At 24h after infection, virus titers
in the media were 6.3 10
4PFUml
–1 when Hh101-
infected carrier cells were administered, and only
2.1 10
2PFUml
–1 when Hh101 virus was administered.
Moreover, CPE was observed B12h after infection
when Hh101-infected carrier cells were administered
(Figure 4a), whereas it was observed 24h after infection
with Hh101 virus alone (Figure 4b). CPE was spread
more rapidly and extensively in the case of Hh101-
infected carrier cells (Figure 4a). Carrier cells therefore
supported sufficient viral replication and could contact
target cancer cells efficiently.
In vitro immune evasion by cell-based delivery of HSV
As the majority of human adults has been exposed to
HSV and has anti-HSV antibodies, it is theoretically
possible that oncolytic virus would be attenuated by
circulating antibodies. To examine the effect of antibodies
Figure 2 HF10 reduces tumor growth in a subcutaneous (s.c.)
ovarian cancer model. (a) In all, 5 10
6 SKOV3 cells were s.c.
implanted into the flank of 5-week-old nude mice. When s.c. tumors
were approximately 10–15mm in diameter, phosphate-buffered
saline (PBS) (control) or 1 10
7 plaque-forming units HF10 were
injected intratumorally on days 8, 10 and 12. (b) Group two was
injected on days 8, 10, 12, 18, 20 and 22. Tumor volume was
monitored for the indicated days after treatment (Po0.01; control vs
HF10 treatment group). Bars represent means þ s.e.m. of each
group. (c) Representative pictures of control (right), group one
(middle) and group two (left) at day 30.
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Cancer Gene Therapyagainst virus delivery by carrier cells, we performed
in vitro experiments. We plated SKOV3 cells on 35-mm
dishes, and after 24h, HF-GFP (10
5PFU per dish) or
HF-GFP-infected carrier cells (10
4 cells per dish) were
added to the culture media containing with anti-HSV-1
antiserum or control serum. As evidenced by virus-associ-
ated fluorescence, extensive replication was seen in
SKOV3 cells 24h following administration of HF-GFP-
Figure 3 HF10 and Hh101 replication in mesothelial cells (MCs), human omentum mesothelial cells (HOmMCs) and SKOV3 cells. SKOV3 cells
(a, black line) and MCs (b, red line) were infected with HF10 at multiplicities of infection (MOI) 3. SKOV3 cells (c, black line) and HOmMCs (d, red
line) were infected with Hh101 at MOI 3. Representative cytopathogenic effects (CPE) are shown as time series. Cells were harvested and virus
titer was determined by plaque assay. The red dotted line shows virus titers in MCs infected with Hh101 at MOI 0.03 (e, f). The values represent
the mean of samples tested in triplicate. PFU, plaque-forming unit.
Figure 4 In vitro delivery of herpes simplex virus (HSV) using mesothelial cells as carriers. Hh101-infected carrier cells (a) or cell-free Hh101
(b) were added to the media of SKOV3 cells. Representative cytopathic effects (CPEs) are shown as time series. The white arrow heads show
small CPEs.
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Cancer Gene Therapyinfected carrier cells in spite of anti-HSV-1 antiserum. In
the absence of anti-HSV-1 antiserum (Figure 5a), how-
ever, virus-associated fluorescence was larger and brighter
than in the presence of anti-HSV-1 antiserum (Figure 5b).
In contrast, little virus-associated GFP was observed in
SKOV3 cells 24h following administration of HF-GFP
in the presence of anti-HSV-1 antiserum (Figure 5d),
although a number of GFP-expressing cells were detect-
able in the absence of anti-HSV-1 antiserum (Figure 5c).
These results indicated that cellular carriers can efficiently
shield oncolytic virus from neutralizing antibodies.
Localization of virally infected cell delivery in the
presence of anti-HSV-1 antiserum
In order to visualize the distribution of the cellular
vehicles in mice, we used HF-GFP, which allowed us to
follow the biodistribution of virus-associated fluorescence
using an in vivo imaging system. To assess the localization
of intraperitoneally injected virus, we established a mouse
model using ovarian cancer cells, in which 2 10
6 SKOV3
cells were inoculated into the peritoneal cavity of nude
mice, leading to the formation of peritoneal dissemina-
tions. HF-GFP was injected into the peritoneal cavity 30
days after the initial inoculation of cancer cells. At 24h
after HF-GFP injection, nearly all visible tumor nodules
in the peritoneal cavity were GFP positive. We detected
GFP expression even in small tumors and the brightness
of GFP varied in each tumor (Figure 6b). In contrast, no
GFP expression was seen in the tumors in animals of the
control group (Figure 6a). The GFP expression persisted
for 7 days after HF-GFP injection; however, the bright-
ness of GFP weakened as time passed. GFP expression
persisted longer in mice injected with HF-GFP-infected
carrier cells than in mice injected with HF-GFP
alone. These findings suggested that viruses injected into
the peritoneal cavity exhibited preferential and specific
distribution in disseminated cancer foci in HSV-1
naı¨ve animals.
Next, to examine the impact of a pre-existing immune
response, we used the passive immunization method in
which anti-HSV-1 antiserum was injected i.p. into mice.
Intraperitoneal tumor-bearing mice were given cell-free
HF-GFP or HF-GFP-infected HOmMCs i.p at 1h after
treatment with anit-HSV-1 antiserum or control serum.
No clear GFP signal was observed in disseminated tumors
when HF-GFP was given to mice pretreated with anti-
HSV-1 antiserum (Figure 6c). In contrast, a significant
GFP signal was detected in peritoneal tumors in spite of
pretreatment with anti-HSV-1 antiserum, suggesting that
infected carrier cells could bypass circulating antibodies
and transfer virus to intraperitoneally disseminated
ovarian tumors (Figure 6d).
Intraperitoneal administration of HSV-1 mutant-infected
carrier cells improved survival of mice with ovarian
cancer
To assess the suitability of carrier cells for the delivery of
HSV-1 mutants in vivo, we conducted survival experi-
ments to compare the effects of Hh101 administered
directly with the effects of Hh101 delivered via HOmMCs.
Because HF10 is lethal to immunodeficient animals, we
utilized Hh101, which is a recombinant virus clone
isolated from HF10 and hrR3 and is less virulent than
HF10. PBS, Hh101 or Hh101-infected carrier cells were
injected three times 3 days after the i.p. injection of
2 10
6 SKOV3 cells, a time at which tumors would be
invisible to the naked eye. Three repeated therapeutic
injections of Hh101-infected HOmMCs significantly
improved the mean survival time of ovarian cancer-
engrafted nude mice (55 days, n¼10) compared with the
administration of Hh101 alone (46 days, n¼9; Po0.05)
(Figure 7a). Two-tenth of the animals in the carrier cell-
treated group were completely protected from relapse of
peritoneal tumor and ascites.
Next, PBS or Hh101-infected carrier cells were injected
five times 6 days after the injection of tumor cells, a time
at which numerous macroscopic white, 2mm diameter
tumors were seen at the diaphragm, at the mesentery and
occasionally at the omentum. As shown in Figure 7b, all
mice, irrespective of treatment, developed macroscopic
Figure 5 In vitro effects of anti-herpes simplex virus type 1 (HSV-1) antibody on HF-green fluorescent protein (GFP). SKOV3 cells were plated
for 24h, and HF-GFP-infected carrier cells (a, b) or HF-GFP (c, d) were added to the media containing control serum (a, c) or anti-HSV-1
antiserum (b, d). Anti-HSV-1 antiserum was added to the media to give a final dilution of 1:50. Representative cytopathogenic effect (CPE)
images are taken at 24h using the Leica M205FA fluorescence stereomicroscope with a standard GFP filter set. SKOV3 cells were then fixed,
stained with 0.2% crystal violet solution and observed at 30h. The number of plaques was counted and expressed as a percentage of number
obtained in control cultures (e).
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However, the survival time was extended by treatment
with Hh101-infected carrier cells. This resulted in an
approximate doubling of the median survival time (45
days; n¼5) compared with that for control animals
receiving PBS alone (28 days; n¼5; Po0.01). Thus,
in both experiments the prognosis was significantly
improved by treatment with Hh101-infected carrier cells.
Discussion
Genetically engineered, conditionally replicating HSV-1 is
a promising therapeutic agent for cancer therapy. The
main antitumor mechanism of oncolytic viruses results
from viral replication within infected tumor cells, result-
ing in cell destruction, and liberation of progeny virus
particles that can directly infect adjacent tumor cells.
7
Figure 6 In vivo visualization of virally infected cell delivery in the presence of anti-herpes simplex virus type 1 (HSV-1) antiserum. Mice were
bearing disseminated SKOV3 ovarian tumors. Mice were randomized into non-treatment group (a, b) and treatment group with anti-HSV-1
antiserum (c, d). Intraperitoneal tumor-bearing mice were given phosphate-buffered saline (PBS) (a), cell-free HF-green fluorescent protein
(GFP) (b, c) or HF-GFP-infected human omentum mesothelial cells (HomMCs) (d) intraperitoneally 1h after treatment. Representative
photographs showing between tumor location and GFP signal. Each picture taken 24h after viral injections is shown. The yellow arrows and
dotted-line circles indicate disseminated ovarian tumor.
Figure 7 Therapeutic effects of Hh101-infected carrier cells in an ovarian cancer model. Nude mice were engrafted intraperitoneally with
SKOV3 cells and (a) treatment was started 3 days later using three repeated i.p. injections. Three repeated therapeutic injections of
Hh101-infected human omentum mesothelial cells (HOmMCs) improved the survival of ovarian cancer-engrafted nude mice. Injections of
Hh101-infected carrier cells were more effective than Hh101 injections alone. Some of the mice treated with Hh101-infected carrier cells survived
without symptoms or site injection tumors for 480 days. (b) Therapy was started on day 6 with five repeated i.p. injections. Median survival
was significantly (P¼0.0018) prolonged for the group of carrier-cell-treated animals compared with the control group (median survival, 45 days
vs 28 days).
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Cancer Gene TherapyMost clinical trials using oncolytic viral therapy have been
performed using direct i.t. injection. However, almost all
HSV-1 mutants were not so effective as expected when
used clinically as antitumor cytolytic agents.
22–24 In an
effort to develop more effective, well-tolerated, novel viral
therapeutic agents, we have focused a highly attenuated
oncolytic HSV-1 mutant, which lacks four accessory
genes (UL56, UL43, UL49.5 and UL55) and LAT
(latency-associated transcript).
17–19 Our previous obser-
vation have shown that the HF10 is a potent novel agent
for oncolytic therapy that is safe and effective for colon
cancer, sarcoma and melanoma treatment in mouse
models.
25–27 We have also performed a clinical trial of
the treatment of recurrent breast cancer and head and
neck cancer using i.t. injection of HF10.
28–30 These results
revealed a potent oncolytic effect of HF10 without any
side effects in human. Currently HF10 is being tested in
the United States for the patients with advanced head and
neck cancer in a Phase I clinical trial. Here, we have
examined the ability of HF10 to control ovarian cancer in
order to apply the HF10 therapy for peritoneally
disseminated ovarian cancer. Firstly, we performed i.t.
therapy of s.c. xenograft tumors using HF10, and tumor
growth was significantly reduced. Moreover, in animals
treated with six injections, a complete disappearance of
the tumor was observed in some animals.
As a strategy to potentially enhance the delivery of
HSV to disseminated tumors and to protect the virus
from inhibitory factors (complement, anti-HSV antibo-
dies) in the peritoneal cavity, we and others are exploring
the use of carrier cells as Trojan Horses to deliver virus
to tumors. The optimal carrier cell should be highly
susceptible to HSV infection, not be rapidly killed by the
virus, traffic to tumors and transfer the viral infection to
the tumor cells via cell-to-cell heterofusion and/or by
production of virus progeny.
11,31,32 An assortment of cells
have been explored in this regard, including tumor
cells,
24,33–35 outgrowth endothelial cells
36 and T cells.
31,37
In this work, we observed an B10-fold higher amplifica-
tion of the virus in HOmMCs than SKOV3 cells in vitro.
Virus replication was the most efficient in HOmMCs, so
we decided to use these cells as HSV carrier cells. Next, we
estimated the efficacy of tumor killing caused by virus-
loaded carrier cells in vitro. Our in vitro studies clearly
demonstrated the efficacy of spread of infection between
tumor cells and carrier cells. The transfer and spread of
infectivity by MCs derived from the omentum was much
higher than infectivity transfer by cell-free viruses. Taken
together, these findings suggested that HOmMCs would
be suitable for use as carrier cells to treat peritoneally
disseminated ovarian cancer. However, the ultimate fear
of carrier cells after intraperitoneal inoculation may pose
some safety concerns. In this study, we immortalized
normal human peritoneal MCs with non-viral human
genes (mutant Cdk4, cyclin D1 and hTERT) and utilized
as carrier cells. Such as the case, a carcinogenic potential
of HOmMCs would not emerge thus far (data not
shown). In the previous study,
21 we have developed
immortalized ovarian surface epithelium with the same
gene sets, and we did not observe any tumorigenesis up to
doublings 60. The possibility of clinical application of
carrier cells warrants that safety would be ensured.
Ascites frequently accumulate in patients who have
tumor spread in the peritoneal cavity, and this fluid is
expected to be rich in anti-HSV antibodies because the
immunoglobulin G content of ascites fluid is known to
reflect that of blood.
38 Also, it has been shown that pre-
existing neutralizing antibodies in ascites may prevent
initial adenovirus vector delivery in ovarian cancer
patients.
39 Thus, carrier cells are expected to be useful
not only for systemic virus delivery but also for
intraperitoneal administration in patients with peritoneal
metastases and pre-existing humoral immune response.
We also examined the effect of antibodies against virus
delivery by carrier cells. Our in vitro data demon-
strated that direct cell-to-cell transfer of infectivity by
HOmMCs was five to six times more resistant to
neutralizing antibodies than infectivity transfer by naked
virus. Thus, once infection is successfully transferred to
the tumor, it is expected that antibodies will not stop i.t.
virus spread. We also showed that HOmMCs infected
with HF-GFP could target pre-established ovarian tumor
nodules in mice (Figure 6), and this result is consistent
with that of measles virus-infected cell carriers.
40 These
data support the potential use of HSV oncolytic therapy
using carrier cells in humans with pre-existing immu-
nity to HSV.
This study supports the concept that the utilization of
carrier cells may have a role in HSV-based oncolytic
therapies. Inoculation of HOmMCs infected at MOI 3 or
the equal titer of HSV particles should represent
comparable viral loads initially administered to the
animals. In the SKOV3 model, the carrier cell strategy
led to a significant prolongation of animal survival
compared with virus alone. Earlier treatment (3 days
after engraftment) with infected carrier cells was even
more effective. Hh101-infected carrier cells rescued few of
the animals, because Hh101 is more attenuated than
HF10, which is lethal for immunodeficient mice. If we use
HF10 for carrier cell-based therapy in an immunocompe-
tent model, we anticipate that the therapeutic effect would
be better and be enhanced. Moreover, the immunogeni-
city of carrier cells may enhance therapy, as the activation
of antitumor immunity during virotherapy appears to
contribute to some degree to eliminating tumors and may
help to protect from disease. To estimate the role of the
immune response in oncolytic viral therapy, we would
need to investigate this theory in a syngeneic immuno-
competent mouse model of disseminated peritoneal
ovarian carcinoma.
In conclusion, we establish that human peritoneal MCs
are useful for carrier cells of oncolytic HSV in treating
peritoneally disseminated ovarian cancer. Infected MCs
and HOmMCs have the unique ability to produce a burst
of virus upon delivery to the tumor site. In addition, this
strategy allowed oncolytic HSV to escape neutralization
by antibodies and complement, and subsequently to
transfer the virus to tumor cells by in situ cell fusion.
These findings may have significant implications for
oncolytic virotherapy for ovarian cancer.
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